First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...

Magnet Biomedicine announced Friday it has reached a licensing agreement worth up to $1.25B with Eli Lilly (NYSE:LLY) to develop cancer drugs leveraging the company’s TrueGlue discovery platform.

Global CEO of Eli Lilly, world’s pioneer Insulin manufacturers, David Ricks called on Union Minister of State (Independent ...

Dr. Jitendra Singh, a renowned endocrinologist himself, emphasized the unique metabolic challenges faced by India due to its ...

Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.

As U.S. President Donald Trump threatens a new round of tariffs as part of an onshoring push, Chinese President Xi Jinping is ...

Crunching the data, the news looks relatively worse for Novo Nordisk and relatively better for rivals Eli Lilly and Him & Hers ... drug from China's The United Bio-Technology (Hengqin) Co. Novo ...

With approximately 101 million individuals living with diabetes, increasing access to insulin and advanced treatments is ...

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...

The Series B round will help the Aditum Bio-backed startup fund two mid-stage clinical trials in people with alcohol and ...